SkylineDX affirmed foraying into a strategic collaboration to curate novel diagnostic tests to enhance clinical decision making for melanoma patients. The Joint development agreement with Mayo Clinic assures development of new diagnostic tests thereby augmenting its product offering to a larger group of patients and clinicians grappling with Melanoma.
The collaboration will aid Mayo Clinic to further advance and optimize algorithm to identify risk factors associated with metastasis, originally discovered and developed by Mayo Clinic dermatologist Alexander Meves, M.D., and his team.
Dharminder S. Chahal, Chief Executive Officer of SkylineDx said “The collaboration with Mayo Clinic is a significant achievement for SkylineDx since this enables us to further extend our product offering by using our knowledge and experience in the field of bio-informatics in other disease areas outside of multiple myeloma, building upon our existing assets and capabilities.”
Image Source : Mayo Clinic